On July 25, 2019 Snap Bio, Inc. and Torrey Pines Investment (TPI) reported that their joint early drug discovery program within the framework of the i2020 Accelerator has resulted in achieving the projected milestone in developing several small molecule lead candidates for treatment of Hepatocellular carcinoma (HCC) and Hepatoblastoma (Press release, Snap Bio, JUL 25, 2019, View Source [SID1234537776]). The milestone is marked with an outstanding selectivity profile and promising overall animal data in rodents for the lead candidates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This timeline-driven achievement was enabled­­ through the synergistic efforts of TPI’s i2020 Accelerator network, which includes ChemDiv, Inc. with its pertinent technical life-sciences expertise and its unique integrated drug discovery platform.

"The i2020 Accelerator was created to help take early stage research programs with differentiated biology and established development paradigms to the level of advanced leads and clinical candidates," comments Ronald Demuth, President of Torrey Pines Investment. "We were excited to start working with Snap Bio, their unique platform that integrates structure-based drug design and advanced synthetic biology allows for scaffold modification to be taken to a new level with improved optimization for all the key properties of highly effective and selective treatments. Snap Bio has been a great fit for our i2020 Accelerator portfolio, and we are glad to be seeing the first fruits of our collaboration thanks to the collective efforts of our global net of partners, including ChemDiv."

"With the help of TPI and the i2020 Accelerator, Snap Bio has discovered novel bispecific inhibitors, opening the door to a platform that offers small molecules with unique combinations of well-defined activities," comments Mark Burk, President and CEO at Snap Bio. "Bispecific small molecules can simultaneously and selectively inhibit two mechanistically distinct targets, which can provide important polypharmacological benefits, such as higher efficacy, fewer side effects, and reduced drug resistance. In addition, relative to drug combination therapies, bispecific inhibitors can target multiple disease pathways without pharmacokinetic disparity, leading to easier, faster, cheaper, and lower risk clinical trials."

About Torrey Pines Investment and i2020

Torrey Pines Investment (San Diego, CA) is a specialty life-science investment firm that invests in development stage molecules, diagnostics, and therapeutics in areas of high unmet medical need. [View Source By rapidly de-risking novel science and enriching partner pipelines with best-in-class molecules, i2020 platform helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year framework. i2020 Accelerator’s vast scientific and global resource network tailored specifically to the needs of early drug development programs allows it to take on projects in a wide array of therapeutic areas, from immunology to infectious diseases and beyond. By successfully leveraging agile development principles and flexible partnering business models, i2020 Accelerator plans to create and invest in multiple small-molecule early drug discovery programs. [www.i2020accelerator.com]

On July 25, 2019 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, reported an update on its oncology programmes (Press release, 4d Pharma, JUL 25, 2019, View Source [SID1234537775]). New preclinical data on the Company’s oncology candidates, MRx0518 and MRx1299, were presented at 1st Microbiome Movement Oncology Response Summit in Boston, USA by Research Director Imke Mulder. A clinical progress update on MRx0518 was also provided by 4D’s Chief Scientific Officer, Alex Stevenson.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MRx1299

MRx1299 is a second-generation Live Biotherapeutic identified by 4D’s MicroRx discovery platform. One of the target host pathways identified for this Live Biotherapeutic is its potent histone deacetylase (HDAC) inhibition mediated by bacterial short-chain fatty acids (SCFAs). HDAC inhibition is thought to have multiple modes of anti-cancer activity, acting on both tumour and immune cells. Treatment with MRx1299 and its metabolites gives cytotoxic T lymphocytes the ability to reduce tumour growth in preclinical cancer models.

MRx0518

0MRx0518, the Company’s lead Live Biotherapeutic candidate in oncology, induces strong innate and adaptive immune responses in vitro and in vivo. New data presented demonstrates the ability of orally administered MRx0518 to modulate the frequency of immune cell populations with anti-tumour activity in the gastrointestinal tract, systemically and in the tumour microenvironment, acting through signalling pathways known to drive anti-cancer immunity.

The Company has previously published data on the mechanism of action of MRx0518 (Lauté-Caly et al. 2019), demonstrating that the bacterial flagellin protein, FliC, strongly activates immunostimulatory NF-κB signalling, via the TLR5 receptor. Research presented at the conference indicates a role for additional host receptors, including TLR9, in mediating the immuno-stimulatory effects of MRx0518.

Alex Stevenson, 4D’s Chief Scientific Officer, commented, "The identification of our new Live Biotherapeutic candidate, MRx1299, strengthens our leading oncology portfolio and expands the scope of oncology indications for our Live Biotherapeutics. MRx1299 has a different mechanism of action to MRx0518 and as such may be suitable for the treatment of different types of cancer. Studies of MRx1299’s efficacy in preclinical models of additional tumour types are ongoing, as is scale-up and process development."

He added, "The additional preclinical data on MRx0518 strengthens our knowledge of its mechanism of action and capacity to launch an immune response against cancer cells. In parallel, data generated from our ongoing clinical studies will assess the ability of MRx0518 to induce these anti-tumour immunological effects in patients. Our Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in patients with solid tumours will provide us with specific biomarker data from both parts of the study. We anticipate the first of this data to be available by the end of 2019."

A copy of the presentations given can be found at View Source

On July 25, 2019 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that it will release its second quarter 2019 financial results on Thursday, August 1, 2019 (Press release, Insmed, JUL 25, 2019, View Source [SID1234537774]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 1, 2019 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 5579948. The call will also be webcast live on the company’s website at www.insmed.com.

A replay of the conference call will be accessible approximately one hour after its completion through August 8, 2019 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing replay access code 10133256. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company’s website at www.insmed.com.

On July 25, 2019 Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, reported that the Company will report financial results for the second quarter ended June 30, 2019 on Thursday, August 8, 2019 after U.S. markets close (Press release, CryoLife, JUL 25, 2019, View Source [SID1234537773]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the earnings release, a document titled "Cryoport Second Quarter 2019 in Review", which will provide a review of Cryoport’s recent financial and operational performance and a general business update, will be issued by management at 4:05 pm ET on Thursday, August 8. The document is designed to be read by investors before the questions and answers conference call and can be accessed at http://ir.cryoport.com/events-and-presentations.

Cryoport management will host a conference call at 5:00 pm ET on August 8, 2019. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results.

Conference Call Information

Date:

Thursday, August 8, 2019

Time:

5:00 p.m. ET

Dial-in numbers:

+1 (855) 327-6837 (U.S.) or +1 (631) 891-4304 (International)

Confirmation code:

Request "Cryoport Call" or provide code 10007349

Live webcast:

‘Investor Relations’ section at www.cryoport.com or at this link. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

An archive of the question and answer webcast will be available approximately three hours after completion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.cryoport.com for a limited time. To access the replay of the webcast, please follow this link. A dial-in replay of the call will also be available to those interested until August 15, 2019. To access the replay, dial +1 (844) 512-2921 (United States) or +1 (412) 317-6671 (International) and enter replay pin number: 10007349.

On July 25, 2019 Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") reported that it will release financial results for the period ended June 30, 2019 and provide a business update prior to market open on Wednesday, July 31, 2019 (Press release, Theravance, JUL 25, 2019, View Source [SID1234537771]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An accompanying conference call will be held at 8:00 am ET on July 31, 2019. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 2445969. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma’s website at www.theravance.com, under the Investor Relations section, Presentations and Events. Please go to the website 15 minutes prior to the start of the call to register, download, and install any necessary audio software.

A replay of the conference call will be available on Theravance Biopharma’s website for 30 days through August 30, 2019. An audio replay will also be available through 11:00 am ET on August 7, 2019 by dialing (855) 859-2056 from the US, or (404) 537-3406 for international callers, and then entering confirmation code 2445969.